comprehensive -WSS

comprehensive

author：comprehensive 2025-09-30 20:35:33 - browse：13759

novavax photo illo — JUSTIN TALLIS/AFP via Getty Images

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, all. Damian here with an update on the plight of the other Covid-19 vaccine company, Wall Street’s latest GLP-1 trade, and the quest for a universal antivenom.

The need-to-know this morning

Ocular Therapeutics announced a shakeup of its senior management team and a $325 million private placement.
Amylyx Therapeutics said results from a closely followed Phase 3 study of its treatment for ALS could come before the start of the second quarter — earlier than previously expected.
Moderna earnings are here.

Novavax’s money is going in the wrong direction

The good news for Novavax is that it’s no longer facing a $700 million dispute with a global charity organization. The bad news is that settling that dispute will force the struggling company to pay out $400 million over the next five years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： HHS secretary Becerra pressed on Change HealthCare cyberattack

hotspot

WSS

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

An inside look at PIPEs, biotech's buzzy new financing tool

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

FDA does about

Why scientists need input from humanists on sensitive research

leisure time

comprehensive

The need-to-know this morning

Novavax’s money is going in the wrong direction

focus

Guidelines to prevent youth baseball injuries need more muscle

How many hemophilia patients actually want gene therapy?

Trump demands the U.S. pay no more for drugs than other countries … again

FDA advisers back CAR

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

New air purifier tech could be key to improving indoor air quality

Boston's new lab space is opening empty

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

entertainment

Steward Health Care Massachusetts hospitals face fiscal disaster

Clinical trials giant ICON acquires HumanFirst

John Green on his newest strategy for fighting tuberculosis

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

FDA advisers back CAR

Male and female sex labels in research insufficient, scientists say

leisure time

hotspot

focus

knowledge